Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus – from the Spanish National Health System perspective

References

• World Health Organization. WHO: noncommunicable diseases country profiles 2014 [Internet]. Geneva (Switzerland): World Health Organization; 2014. [[cited 2014 Sept 15]]. Available from: http://www.who.int/nmh/publications/ncd-profiles-2014/en/
   Google Scholar
• Whiting DR, Guariguata L, Weil C, et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94(3):311–321.
   PubMed Web of Science ®Google Scholar
• Health at a Glance 2011: OECD Indicators [Internet]. 2011 OECD iLibrary; [cited 2014 Sept 15]. Available from: http://www.oecd-ilibrary.org/sites/health_glance-2011-en/01/10/index.html;jsessionid=1agb3d4ehfyfy.x-oecd-live-01?itemId=/content/chapter/health_glance-2011-13-en&_csp_=e25d9e9cf4373302c9fcef4e6b64239f.
   Google Scholar
• Giralt Muiña P, Ballester Herrera MJ, Palomo Atance E, et al. Estudio epidemiológico de la diabetes tipo 1, en menos de 15 años en Castilla-La Mancha [Epidemiological study of type 1 diabetes in less than 15 years in Castilla-La Mancha]. An Pediatr (Barc). 2012;76(2):83–91.
   PubMed Web of Science ®Google Scholar
• IMAGE project: Development and Implementation of a European Guideline and Training Standards for Diabetes prevention [Internet]. 2010. IMAGE project [cited 2014 Sept 15]. Available from: http://www.image-project.eu/.
   Google Scholar
• Guías Clínicas-Diabetes Mellitus Clinical Guidelines-Diabetes Mellitus [Internet].Fisterra; 2014 [cited 2014 Sept 15]. Available from: http://www.fisterra.com/guias-clinicas/diabetes-mellitus-tipo-2/#21311.
   Google Scholar
• Brod M, Christensen T, Thomsen TL, et al. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health. 2011;14(5):665–671.
   PubMed Web of Science ®Google Scholar
• DCCT Research group. Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care. 1995;18:1415–1427.
   PubMed Web of Science ®Google Scholar
• Orozco-Beltrán D, Mezquita-Raya P, Ramírez De Arellano A, et al. Incidence and frequency of patient-reported hypoglycaemic events in Spain. Poster submitted to ADA Congress; 2013 June 21; Chicago (USA).
   Google Scholar
• La sociedad Española de Diabetes analiza el uso de la insulina glargina [The Spanish society of Diabetes analyses the use of insulin glargine] [Internet]. 2004 Fundación Diabetes; [cited 2014 Sept 15] Available at: www.fundaciondiabetes.org/upload/noticias/3427/71.pdf.
   Google Scholar
• Principios activos: InsulinaGlargina [Active ingredients: Insulin Glargine] [Internet]. Vademecum; 2014 [cited 2014 Sept 15]. Available from: http://www.vademecum.es/principios-activos-insulina+glargina-a10ae04.
   Google Scholar
• Rodbard HW, Gough S, Lane W, et al. Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of Basal insulin: a meta-analysis of 5 randomized begin trials. Endocr Pract. 2013;20(4):285–292.
   Web of Science ®Google Scholar
• Ratner R, Gough S, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared to insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013;15(2):175–184.
   PubMed Web of Science ®Google Scholar
• Onishi Y, Iwamoto Y, Jib Yoo S, et al. Insulin degludec compared with insulin glargine in insuline-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial. J Diabetes Investig. 2013;4(6):605–612.
   PubMed Web of Science ®Google Scholar
• Los costes de la diabetes, directamente relacionados con la existencia de complicaciones [The costs of diabetes, directly related to the existence of complications] [Internet]. 2014. Economia de la Salud [cited 2014 Sept 15]. Available from: www.economiadelasalud.com/ediciones/…/analisiscostesdeladiabetes.pdf.
   Google Scholar
• Chaturvedi N. The burden of diabetes and its complications: trends and implications for intervention. Diabetes Res Clin Pract. 2007;76(3):S3–S12.
   PubMed Web of Science ®Google Scholar
• Sacristán JA, Oliva J, Del Llano J, et al. What is an efficient health technology in Spain? Gac Sanit. 2002;16(4):334–343.
   PubMedGoogle Scholar
• Evans M, Wolden M, Gundgaard J, et al. Cost-effectiveness of insulin degludec compared with insulin glargine in a basal –bolus regimen in patients with type 1 diabetes mellitus in the UK. J Med Econ. 2015;18(1):56–68.
   PubMed Web of Science ®Google Scholar
• Ericsson A, Pollock RF, Hunt B, et al. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden. J Med Econ. 2013;16(12):1442–1452.
   PubMedGoogle Scholar
• Evans M, Wolden M, Gundgaard J, et al. Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin- from the UK health care cost perspective. Diabetes Obes Metab. 2014;16(4):366–375.
   PubMed Web of Science ®Google Scholar
• Evans M, Chubb B, Gundgaard J. Cost-effectiveness of insulin degludec versus insulin glargine in adults with type 1 and type 2 diabetes mellitus. Diabetes Ther. 2017;8(2):275–291.
   PubMed Web of Science ®Google Scholar
• Evans M, Khunti K, Mamdani M, et al. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey of five countries. Health Qual Life Outcomes. 2013;11(9):90.
   PubMed Web of Science ®Google Scholar
• Simon J, Gray A, Clarke P, et al. Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial. BMJ. 2008;336(7654):1177–1180.
   PubMed Web of Science ®Google Scholar
• Vora J, Christensen T, Rana A, et al. Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials. Diabetes Therapy. 2014;5(2):435–446.
   PubMed Web of Science ®Google Scholar
• King AB. No higher dose requirements with insulin detemir than glargine in type 2 diabetes: a crossover, double-blind, and randomized study using continuous glucose monitoring. J Diabetes Sci Technol. 2010;4(1):151–154.
   PubMedGoogle Scholar
• Orozco-Beltrán D, Mezquita-Raya P, Ramírez De Arellano A, et al. Self-reported frequency and impact of hypoglycemic events in Spain. Diabetes Therapy. 2014;5(1):155–168.
   PubMed Web of Science ®Google Scholar
• Philis-Tsimikas A, Brod M, Niemeyer M, et al. Insulin degludec once-daily in type 2 diabetes: simple or step-wise titration (BEGIN: once simple use). Adv Ther. 2013;30(6):607–622.
   PubMed Web of Science ®Google Scholar
• BOT Plus web. Base de datos de medicamentos del consejo general de colegios Farmacéuticos [Drug Database of the General Council of Pharmaceutical Colleges]. BOT Plus; [ cited 2014 Jul 20]. Available from: https://botplusweb.portalfarma.com/
   Google Scholar
• Data not published. Novo Nordisk Tender HUC-CA-022/10 resolution date. 2011 06 20.
   Google Scholar
• Hammer M, Lammert M, Mejias SM, et al. Costs of managing severe hypoglycaemia in three European countries. J Med Econ. 2009;12(4):281–290.
   PubMedGoogle Scholar
• The role of B.I.R.O in implementing the diabetes EU Policy Recommendations. A policy document by the B.I.R.O EU Project Consortium [Internet]. BIRO; 2006 [cited 2014 Jul 20]. Accessible from: http://www.biro-project.eu
   Google Scholar
• Yang L, Christensen T, Sun F, et al. Cost-effectiveness of switching patients with type 2 diabetes from insulin glargine to insulin detemir in Chinese setting: a health economic model based on the PREDICTIVE study. Value Health. 2012;15(1):S56–59.
   PubMed Web of Science ®Google Scholar
• Pfohl M, Schädlich PK, Dippel FW, et al. Health evaluation of insulin glargine vs NPH insulin in intensified conventional therapy for type 1 diabetes in Germany. J Med Econ. 2012;15(2):14–27.
   PubMedGoogle Scholar
• Pollock RF, Curtis BH, Valentine WJ. A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States. J Med Econ. 2012;15(4):766–775.
   PubMedGoogle Scholar
• Kamble S, Schluman KA, Reed SD. Cost-effectiveness of sensor-augmented pump therapy in adults with type 1 diabetes in the United States. Value Health. 2012;15(5):632–638.
   PubMed Web of Science ®Google Scholar
• Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Eng J Med. 2007;257(17):1716–1730.
   Web of Science ®Google Scholar
• Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007;18(2):CD005613.
   Google Scholar
• Farcasiu E, Ivanyi T, Mozejko-Pastewka B, et al. Efficacy and safety or prandial premixed therapy using insulin lispro mix 50/50 3 times daily compared with progressive titration of insulin lispro mix 75/25 or biphasic insulin aspart 70/30 twice daily in patients with type 2 diabetes mellitus: a randomized, 16-week, open-label study. Clin Ther. 2011;33(11):1682–1693.
   PubMed Web of Science ®Google Scholar
• Poley MJ, Stolk EA, Tibboel D, et al. The Cost-Effectiveness of Treatment for congenital diaphragmatic Hernia. J Pediatr Surg. 2002;37(9):1245–1252.
   PubMed Web of Science ®Google Scholar
• Gaber AM, Phelps CE. Future cost and the future of cost-effectiveness analysis. J Health Econ. 2008;27(4):819–821.
   PubMed Web of Science ®Google Scholar
• Donnelly LA, Morris AD, Frier BM, et al. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type2 diabetes: a population based study. Diabet Med. 2005;22(6):749–755.
   PubMed Web of Science ®Google Scholar
• Henderson JN, Allen KV, Deary IJ, et al. Hypoglycaemia in insulin-treated Type 2 diabetes: frequency, symptoms and impaired awareness. Diabet Med. 2003;20(12):1016–1021.
   PubMed Web of Science ®Google Scholar
• Ahrén B. Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Manag. 2013;9:155–163.
   PubMedGoogle Scholar
• Henderson JN, Allen KV, Deary IJ, et al. Hypoglycemia in insulin-treated Type 2 diabetes: frequency, symptoms and impaired awareness. Diabet Med. 2003;20(12):1016–1021.
   PubMed Web of Science ®Google Scholar